ProMIS Neurosciences reports Q3 EPS (24c) vs 31c last year

“2025 has been a year of intense focus and successful execution for the team at ProMIS,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences (PMN). “We have reinforced the Company’s strong foundation both strategically and clinically by bringing in additional capital to support our stated goals and adding Slanix Paul Alex, Pharm.D., President and Portfolio Manager for Ally Bridge Group’s Public Equity strategy to our Board. Collectively, this amplifies awareness amongst the investment community as we approach the nearing completed enrollment of our PRECISE-AD trial evaluating our first clinical candidate, PMN310, which was designed using our proprietary EpiSelect computational drug discovery engine. All of this is ultimately preparing the Company for its multiple key anticipated inflection points in 2026 and endeavoring to deliver on its promise of developing next-generation therapies for AD and for other neurogenerative disorders.”